SDRF template for clinical study samples with treatment, demographics, and lifestyle metadata. Applicable to any organism. Combine with organism template (human, vertebrates) and technology template (ms-proteomics, affinity-proteomics).
The clinical-metadata template captures treatment, demographics, and lifestyle data for
interventional and observational studies. It extends sample-metadata and is also the parent
of oncology-metadata.
Key guidance:
characteristics[compound] + characteristics[dose] +characteristics[exposure duration] together for detailed pharmacological annotation.
characteristics[treatment]: Broader treatment description. Use untreated for controls.characteristics[treatment status]: When the sample was collected relative to treatment(pre-treatment, on treatment, post-treatment, treatment naive).
characteristics[treatment response]: Clinical response assessment (complete response,partial response, progressive disease, stable disease).
characteristics[sampling time]: Time of collection with unit (0 hour, 24 hour,7 day). Critical for time-course and pharmacokinetic studies.
characteristics[sampling site]: Anatomical context (tumor, normal tissue adjacent totumor). Important for matched tissue designs.
characteristics[genotype]: Known genetic variants (BRCA1 mutation carrier, wild type).characteristics[phenotype]: Observable characteristics (drug resistant, HER2-positive).| Column | Requirement | Source | Description | |
|---|---|---|---|---|
| characteristics[disease] | required | clinical-metadata | Disease state of the sample | |
|
Disease state of the sample
ontology
— ontologies: mondo, efo, doid, ncit, pato
The disease should be a valid MONDO, EFO, DOID, NCIT, or PATO ontology term. Use 'normal' (PATO:0000461) for healthy samples.
normal, breast cancer, infection, metabolic disease
|
||||
| characteristics[compound] | optional | clinical-metadata | Chemical compound or drug applied to sample | |
|
Chemical compound or drug applied to sample
ontology
— ontologies: chebi, ncit, efo
The compound should be a valid ChEBI, NCIT, or EFO term
doxorubicin, cisplatin, tamoxifen, metformin
|
||||
| characteristics[dose] | optional | clinical-metadata | Dose or concentration of compound treatment | |
|
Dose or concentration of compound treatment
number_with_unit
Dose with unit
10 mg/kg, 50 uM, 100 nM, 5 mg
|
||||
| characteristics[exposure duration] | optional | clinical-metadata | Duration of treatment exposure | |
|
Duration of treatment exposure
number_with_unit
Exposure duration with time unit
24 hour, 5 day, 30 minute, 2 week
|
||||
| characteristics[treatment status] | optional | clinical-metadata | Treatment status at time of sampling | |
|
Treatment status at time of sampling
values
— values:
pre-treatment, on treatment, post-treatment, treatment naive
Treatment status
|
||||
| characteristics[treatment response] | optional | clinical-metadata | Response to treatment (for studies measuring therapeutic outcomes) | |
|
Response to treatment (for studies measuring therapeutic outcomes)
ontology
— ontologies: ncit
Treatment response should be a valid NCIT term
complete response, partial response, progressive disease, stable disease
|
||||
| characteristics[pre-existing condition] | optional | clinical-metadata | Pre-existing medical conditions or comorbidities | |
|
Pre-existing medical conditions or comorbidities
ontology
— ontologies: mondo, efo, doid
Pre-existing condition should be a valid MONDO, EFO, or DOID term
diabetes mellitus, hypertension, obesity
|
||||
| characteristics[body mass index] | optional | clinical-metadata | Body mass index (BMI) in kg/m^2 | |
|
Body mass index (BMI) in kg/m^2
pattern
— pattern:
^[\d.]+$
Numeric BMI value
24.5, 31.2, 18.7
|
||||
| characteristics[smoking status] | optional | clinical-metadata | Patient smoking status | |
|
Patient smoking status
ontology
— ontologies: ncit
Smoking status should be a child term of NCIT:C19796
never smoker, former smoker, current smoker
|
||||
| characteristics[menopausal status] | optional | clinical-metadata | Menopausal status for female patients | |
|
Menopausal status for female patients
values
— values:
pre-menopausal, peri-menopausal, post-menopausal
Menopausal status
|
||||
| characteristics[genetic modification] | optional | clinical-metadata | Method of genetic modification (knockout, knockdown, overexpression, transduction) | |
|
Method of genetic modification (knockout, knockdown, overexpression, transduction)
ontology
— ontologies: efo
Genetic modification method should be a valid EFO term
knockout, knockdown, overexpression, transduction, CRISPR-Cas9
|
||||
| characteristics[phenotype] | optional | clinical-metadata | Observable characteristics or traits (drug sensitivity, molecular markers, expression phenotypes) | |
|
Observable characteristics or traits (drug sensitivity, molecular markers, expression phenotypes)
ontology
— ontologies: pato, efo
Phenotype should be a valid PATO or EFO term, or free text
drug resistant, HER2-positive, high expresser, wild-type phenotype
|
||||
| characteristics[weight] | optional | clinical-metadata | Body weight of the subject | |
| characteristics[height] | optional | clinical-metadata | Height of the subject | |
| characteristics[sampling site] | optional | clinical-metadata | Specific anatomical location or context of sampling within the organism part | |
|
Specific anatomical location or context of sampling within the organism part
ontology
— ontologies: uberon, bto
Sampling site should be a valid UBERON or BTO term, or a descriptive term
tumor, normal tissue adjacent to tumor, left ventricle, frontal cortex
|
||||
| characteristics[genotype] | optional | clinical-metadata | Known genetic variant, mutation, or genotype of the subject | |
|
Known genetic variant, mutation, or genotype of the subject
pattern
— pattern:
^.+$
Genotype as free text (gene name + variant)
BRCA1 mutation carrier, KRAS G12D mutant, wild type, TP53 R175H
|
||||